WO2005091805A3 - Methods and compositions for inhibition of metastasis - Google Patents
Methods and compositions for inhibition of metastasis Download PDFInfo
- Publication number
- WO2005091805A3 WO2005091805A3 PCT/US2005/004612 US2005004612W WO2005091805A3 WO 2005091805 A3 WO2005091805 A3 WO 2005091805A3 US 2005004612 W US2005004612 W US 2005004612W WO 2005091805 A3 WO2005091805 A3 WO 2005091805A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- metastasis
- inhibition
- metastatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05760713A EP1725111A4 (en) | 2004-02-13 | 2005-02-14 | Methods and compositions for inhibition of metastasis |
CA002559480A CA2559480A1 (en) | 2004-02-13 | 2005-02-14 | Methods and compositions for inhibition of metastasis |
JP2006553317A JP2007523650A (en) | 2004-02-13 | 2005-02-14 | Methods and compositions for inhibiting metastasis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54480704P | 2004-02-13 | 2004-02-13 | |
US60/544,807 | 2004-02-13 | ||
US62672604P | 2004-11-10 | 2004-11-10 | |
US60/626,726 | 2004-11-10 | ||
US11/056,825 US7271245B2 (en) | 2004-02-13 | 2005-02-11 | Methods and compositions for inhibition of metastasis |
US11/056,825 | 2005-02-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005091805A2 WO2005091805A2 (en) | 2005-10-06 |
WO2005091805A3 true WO2005091805A3 (en) | 2006-09-08 |
Family
ID=35056641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/004612 WO2005091805A2 (en) | 2004-02-13 | 2005-02-14 | Methods and compositions for inhibition of metastasis |
Country Status (5)
Country | Link |
---|---|
US (2) | US7271245B2 (en) |
EP (1) | EP1725111A4 (en) |
JP (1) | JP2007523650A (en) |
CA (1) | CA2559480A1 (en) |
WO (1) | WO2005091805A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004003144A2 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
AR045563A1 (en) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
KR101263079B1 (en) | 2005-07-18 | 2013-05-09 | 암젠 인크 | Human anti-b7rp1 neutralizing antibodies |
EP2082234B1 (en) * | 2006-11-02 | 2012-10-03 | Procognia (Israel) Ltd. | Methods for screening for therapeutic molecules and use of the molecules therefrom |
US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
WO2009042917A1 (en) * | 2007-09-28 | 2009-04-02 | The General Hospital Corporation | Methods and compositions for antibody production |
WO2009070753A2 (en) * | 2007-11-28 | 2009-06-04 | The Scripps Research Institute | Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject |
MX2010007101A (en) * | 2007-12-26 | 2011-07-01 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells. |
WO2009114816A2 (en) * | 2008-03-14 | 2009-09-17 | The Board Of Trustees Of The University Of Illinois | Therapeutic cancer antigens |
WO2010017083A1 (en) * | 2008-08-04 | 2010-02-11 | Wayne State University | Methods of treating cancer with cd11b antibodies |
US11180812B2 (en) | 2012-08-17 | 2021-11-23 | Cornell University | Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease |
JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
RU2015143696A (en) | 2013-03-14 | 2017-04-19 | Байер Хелскеа Ллк | MONOCLONAL ANTIBODIES AGAINST β ANTITROMBIN |
CA2924603A1 (en) * | 2013-09-30 | 2015-04-02 | X-Body, Inc. | Antigen receptor screening assay |
WO2015153732A2 (en) | 2014-04-01 | 2015-10-08 | Cornell University | Use of double-stranded dna in exosomes: a novel biomarker in cancer detection |
US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
WO2019241847A1 (en) * | 2018-06-22 | 2019-12-26 | Baker Heart and Diabetes Institute | A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof |
EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
ATE175241T1 (en) * | 1992-04-03 | 1999-01-15 | Genentech Inc | ANTIBODIES AGAINST ALPHA V BETA 3 INTEGRIN |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
KR0119887B1 (en) * | 1994-06-08 | 1997-10-30 | 김광호 | Wafer burn-in testing circuit of semiconductor memory device |
US6596850B1 (en) * | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
WO1998046265A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Methods for using antagonistic anti-avb3 integrin antibodies |
WO1998046264A1 (en) * | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US6406693B1 (en) * | 1998-07-13 | 2002-06-18 | Board Of Regents, The University Of Texas System | Cancer treatment methods using antibodies to aminophospholipids |
WO2000034780A2 (en) * | 1998-12-04 | 2000-06-15 | Novartis Ag | METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
US6531580B1 (en) * | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
WO2002008280A2 (en) * | 2000-07-26 | 2002-01-31 | The Burnham Institute | SCREENING METHODS BASED ON SUPERACTIVATED αVβ3 INTEGRIN |
WO2003034995A2 (en) * | 2001-10-22 | 2003-05-01 | The Scripps Research Institute | Integrin targeting compounds |
WO2003075957A1 (en) * | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
-
2005
- 2005-02-11 US US11/056,825 patent/US7271245B2/en not_active Expired - Fee Related
- 2005-02-14 JP JP2006553317A patent/JP2007523650A/en not_active Withdrawn
- 2005-02-14 WO PCT/US2005/004612 patent/WO2005091805A2/en active Search and Examination
- 2005-02-14 EP EP05760713A patent/EP1725111A4/en not_active Withdrawn
- 2005-02-14 CA CA002559480A patent/CA2559480A1/en not_active Abandoned
-
2007
- 2007-08-01 US US11/832,570 patent/US20090117096A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
FELDING-HABERMANN B. ET AL.: "Involvement of Tumor Cell Integrin Alpha v Beta 3 in Hematogenous Metastasis of Human Melanoma Cells", CLIN. EXP. METASTASIS, vol. 19, no. 5, 2002, pages 427 - 436, XP019235607 * |
VACCA A. ET AL.: "avbeta3 Integrin Engagement Modulates cell Adhesion, Proliferation, and Protease Secretion in Human Lymphoid Tumor Cells", EXP. HEMATOL., vol. 29, no. 8, August 2001 (2001-08-01), pages 993 - 1003, XP008097563 * |
Also Published As
Publication number | Publication date |
---|---|
JP2007523650A (en) | 2007-08-23 |
US20090117096A1 (en) | 2009-05-07 |
CA2559480A1 (en) | 2005-10-06 |
US20050255109A1 (en) | 2005-11-17 |
EP1725111A4 (en) | 2008-08-06 |
EP1725111A2 (en) | 2006-11-29 |
WO2005091805A2 (en) | 2005-10-06 |
US7271245B2 (en) | 2007-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005091805A3 (en) | Methods and compositions for inhibition of metastasis | |
WO2006052823A3 (en) | Biomarkers for prostate cancer metastasis | |
WO2007109254A3 (en) | Stabilized polypeptide compositions | |
WO2006084264A3 (en) | Cd20 antibody variants and uses thereof | |
EP2383297B8 (en) | Optimized antibodies that target CD19 | |
WO2007075891A3 (en) | Multiplex assays using magnetic and non-magnetic particles | |
IL205511A0 (en) | Methods and compositions for the production of monoclonal antibodies | |
IL176940A (en) | Isolated antibody or an antigen binding fragment thereof that binds ige | |
WO2006089125A3 (en) | Methods of detecting ovarian cancer | |
IL227753A0 (en) | Modified antibody or antibody fragment | |
WO2006017538A3 (en) | Hk1-binding proteins | |
WO2006058237A3 (en) | Polymer-coated substrates for binding biomolecules and methods of making and using thereof | |
WO2007133290A8 (en) | Anti-ox40l antibodies and methods using same | |
IL206710A0 (en) | Il-31 monoclonal antibodies | |
WO2007130697A3 (en) | Anti-ephb4 antibodies and methods using same | |
WO2008055080A3 (en) | Method for blocking non-specific protein binding on a functionalized surface | |
IL178422A0 (en) | Antibodies of angiogenesis inhibiting domains of cd148 | |
WO2006131659A3 (en) | Fast binder compositions for concrete parts and works containing a calcium salt | |
WO2007042809A3 (en) | Antibody polypeptide library screening and selected antibody polypeptides | |
SG120312A1 (en) | Sputter target material for improved magnetic layer | |
WO2008112192A3 (en) | Epha3 antibodies for the treatment of solid tumors | |
IL177239A0 (en) | Monoclonal antibody based biomarker discovery and development platform | |
WO2006039678A3 (en) | Establishment of highly metastatic cell lines using nog mice | |
IL185206A0 (en) | Pharmacogenomic markers for prognosis of solid tumors | |
WO2006116703A3 (en) | Methods and models for stress-induced analgesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2559480 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006553317 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005760713 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005760713 Country of ref document: EP |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |